Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities
- PMID: 33637890
- PMCID: PMC8440599
- DOI: 10.1038/s41431-021-00830-z
Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities
Abstract
Hypertension, obesity, chronic kidney disease and type 2 diabetes are comorbidities that have very high prevalence among persons with hyperuricemia (serum urate > 6.8 mg/dL) and gout. Here we use multivariate genetic models to test the hypothesis that the co-association of traits representing hyperuricemia and its comorbidities is genetically based. Using Bayesian whole-genome regression models, we estimated the genetic marker-based variance and the covariance between serum urate, serum creatinine, systolic blood pressure (SBP), blood glucose and body mass index (BMI) from two independent family-based studies: The Framingham Heart Study-FHS and the Hypertension Genetic Epidemiology Network study-HyperGEN. The main genetic findings that replicated in both FHS and HyperGEN, were (1) creatinine was genetically correlated only with urate and (2) BMI was genetically correlated with urate, SBP, and glucose. The environmental covariance among the traits was generally highest for trait pairs involving BMI. The genetic overlap of traits representing the comorbidities of hyperuricemia and gout appears to cluster in two separate axes of genetic covariance. Because creatinine is genetically correlated with urate but not with metabolic traits, this suggests there is one genetic module of shared loci associated with hyperuricemia and chronic kidney disease. Another module of shared loci may account for the association of hyperuricemia and metabolic syndrome. This study provides a clear quantitative genetic basis for the clustering of comorbidities with hyperuricemia.
© 2021. The Author(s), under exclusive licence to European Society of Human Genetics.
Conflict of interest statement
AIV has received consultant fees from University of Alabama at Birmingham and University of Texas, Austin. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee.
Figures


Similar articles
-
Local genetic covariance between serum urate and kidney function estimated with Bayesian multitrait models.G3 (Bethesda). 2022 Aug 25;12(9):jkac158. doi: 10.1093/g3journal/jkac158. G3 (Bethesda). 2022. PMID: 35876900 Free PMC article.
-
Serum urate gene associations with incident gout, measured in the Framingham Heart Study, are modified by renal disease and not by body mass index.Rheumatol Int. 2016 Feb;36(2):263-70. doi: 10.1007/s00296-015-3364-4. Epub 2015 Oct 1. Rheumatol Int. 2016. PMID: 26427508 Free PMC article.
-
Comorbidities in gout and hyperuricemia: causality or epiphenomena?Curr Opin Rheumatol. 2020 Mar;32(2):126-133. doi: 10.1097/BOR.0000000000000691. Curr Opin Rheumatol. 2020. PMID: 31876630 Review.
-
Causal impact of human blood metabolites and metabolic pathways on serum uric acid and gout: a mendelian randomization study.Front Endocrinol (Lausanne). 2024 Jul 4;15:1378645. doi: 10.3389/fendo.2024.1378645. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39027467 Free PMC article.
-
The Shared Genetic Basis of Hyperuricemia, Gout, and Kidney Function.Semin Nephrol. 2020 Nov;40(6):586-599. doi: 10.1016/j.semnephrol.2020.12.002. Semin Nephrol. 2020. PMID: 33678313 Review.
Cited by
-
Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and gout in US adults: a cross-sectional study of the mediating role of BMI.Diabetol Metab Syndr. 2025 Jun 18;17(1):223. doi: 10.1186/s13098-025-01798-2. Diabetol Metab Syndr. 2025. PMID: 40533846 Free PMC article.
-
Using multiple Mendelian randomization approaches and genetic correlations to understand obesity, urate, and gout.Sci Rep. 2021 Sep 7;11(1):17799. doi: 10.1038/s41598-021-97410-4. Sci Rep. 2021. PMID: 34493793 Free PMC article.
-
The Role of Uric Acid in Human Health: Insights from the Uricase Gene.J Pers Med. 2023 Sep 20;13(9):1409. doi: 10.3390/jpm13091409. J Pers Med. 2023. PMID: 37763176 Free PMC article. Review.
-
Uncovering covariance patterns across energy balance traits enables the discovery of new obesity-related genes.Obesity (Silver Spring). 2025 Jun;33(6):1184-1194. doi: 10.1002/oby.24291. Epub 2025 May 26. Obesity (Silver Spring). 2025. PMID: 40415527 Free PMC article.
-
Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes.Saudi Med J. 2025 Mar;46(3):213-225. doi: 10.15537/smj.2025.46.3.20240920. Saudi Med J. 2025. PMID: 40096971 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
- U01 HL054472/HL/NHLBI NIH HHS/United States
- U01 HL054509/HL/NHLBI NIH HHS/United States
- R01 GM101219/GM/NIGMS NIH HHS/United States
- P30 DK079626/DK/NIDDK NIH HHS/United States
- N01 HC025195/HL/NHLBI NIH HHS/United States
- HHSN268201500001I/HL/NHLBI NIH HHS/United States
- K01 AR060848/AR/NIAMS NIH HHS/United States
- P50 AR060772/AR/NIAMS NIH HHS/United States
- U01 HL054495/HL/NHLBI NIH HHS/United States
- R01 DK062148/DK/NIDDK NIH HHS/United States
- HHSN268201500001C/HL/NHLBI NIH HHS/United States
- N02 HL064278/HL/NHLBI NIH HHS/United States
- R01 HL055673/HL/NHLBI NIH HHS/United States
- U01 HL054473/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical